Kathryn Murie

Kathryn Murie

Auto-generated profile, based on publicly available information

Kathryn Murie

Department of Medicine, University of California, San Francisco, California, United States of America

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
TKThomas Katairo
Thomas Katairo
VAVictor Asua
Victor Asua
FSFrancis D. Semakuba
Francis D. Semakuba
BNBienvenu Nsengimaana
Bienvenu Nsengimaana
SKShahiid Kiyaga
Shahiid Kiyaga
MCMelissa D. Conrad
Melissa D. Conrad
The emergence and spread of drug resistance threatens malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria, sequenced using the MAD 4 HatTeR panel and Illumina platforms. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.

15 June 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
TKThomas Katairo
Thomas Katairo
VAVictor Asua
Victor Asua
FSFrancis D. Semakuba
Francis D. Semakuba
BNBienvenu Nsengimaana
Bienvenu Nsengimaana
SKShahiid Kiyaga
Shahiid Kiyaga
MCMelissa D. Conrad
Melissa D. Conrad
The emergence and spread of drug resistance threaten malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Ten thousand thirty samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria and sequenced using the MAD 4 HatTeR panel and Illumina platforms; of these, 8,518 passed quality control and were analyzed. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y, and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.

1 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SRShazia Ruybal-Pesántez
Shazia Ruybal-Pesántez
JAJorge Amaya-Romero
Jorge Amaya-Romero
SBSophie Bérubé
Sophie Bérubé
NBNicholas F. Brazeau
Nicholas F. Brazeau
MDMouhamadou Fadel Diop
Mouhamadou Fadel Diop
RVRobert Verity
Robert Verity
Major advances in Plasmodium sequencing approaches, bioinformatic pipelines, and data analysis tools have provided valuable insights into malaria epidemiology from parasite genomic data. However, translating genetic data into actionable information for decision-makers remains a challenge. Significant barriers limit the integration of these advances into a functional data analysis ecosystem that produces standardized, interpretable results for use by national malaria control programs. The Plasmodium Genomic Epidemiology (PlasmoGenEpi) network convened 18 subject matter experts across 15 institutions at the R eproducibility, A ccessibility, D ocumentation, and I nteroperability S tandards H ackathon in 20 23 (RADISH23) to identify available analysis tools, evaluate software standards, improve documentation, and outline workflows. Eight use cases for genomic data were identified, and a subset were developed into analysis workflows in terms of a series of connected functionalities. Software tools were then mapped against functionalities to outline a modular approach to data analysis for these use cases. In addition to outlining workflows, a set of objective criteria were developed for evaluating software standards. Forty Plasmodium genomic analysis tools were identified, of which 22 were prioritized for software standards evaluation. Additional tutorials were developed for 10 tools in the form of reproducible code applied to shared datasets. These resources are available on PGEforge ( mrc- ide.github.io/PGEforge ), a new community resource that serves as a central, open repository for current and future resources for malaria genomic data analysis.

12 December 2025 in bioRxiv
Verified
Preprint
Open access
NHNicholas J. Hathaway
Nicholas J. Hathaway
KMKathryn Murie
Kathryn Murie
MMMaxwell Murphy
Maxwell Murphy
ASAlfred Simkin
Alfred Simkin
JAJorge Amaya-Romero
Jorge Amaya-Romero
BGBryan Greenhouse
Bryan Greenhouse
Structured Motivation: The rapid increase in the generation of targeted sequencing data offers immense potential for research, medicine, and public health, however the lack of an established standard for these data has led to disparate solutions for data storage. A widely accepted standard is essential for data sharing, reuse, and the coordinated development of interoperable analysis tools. Results: We propose the Portable Microhaplotype Object (PMO), a standardized format for efficiently and losslessly storing phased targeted sequencing data (microhaplotypes). The PMO format is JSON-based, allowing efficient, relational storage of genetic data together with relevant metadata to minimize orphaned data. The format includes required fields and a curated set of optional fields leveraging established ontologies. To facilitate ease of use, we developed pmotools-python, an open-source package for creating, manipulating, and exporting PMO data into common formats. Additionally, we provide a simple web-based app to quickly create PMO files from tabular inputs, making the format accessible to a wide variety of users. Example datasets from Plasmodium, Anopheles, Escherichia coli , and Staphylococcus aureus demonstrate the broad applicability of the approach. PMO will streamline data sharing, foster interoperability, and accelerate the development of harmonized analysis tools. Availability and implementation: The Portable Microhaplotype Object (PMO) project, including the ontology specification, software tools, example datasets, and tutorials, is freely available at https://plasmogenepi.github.io/PMO_Docs/ . Key software components and datasets have archived releases with DOIs to ensure permanence, detailed in the Supplementary Text 1-5. Contact: kathrynmmurie@gmail.com or nickjhathaway@gmail.com

29 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
FSFrancis D. Semakuba
Francis D. Semakuba
BNBienvenu Nsengimaana
Bienvenu Nsengimaana
MMMonica Mbabazi
Monica Mbabazi
TKThomas Katairo
Thomas Katairo
KMKathryn Murie
Kathryn Murie
JBJessica Briggs
Jessica Briggs
Genomic tools can support malaria control policy through surveillance of Plasmodium falciparum populations, tracking antimalarial drug resistance, pfhrp2/3 deletions that compromise rapid diagnostic tests, and selection at the circumsporozoite protein (PfCSP) vaccine target, as well as through molecular correction of therapeutic efficacy studies (TES). Multiplex Amplicons for Drug, Diagnostic, Diversity, and Differentiation Haplotypes using Targeted Resequencing (MAD 4 HatTeR), a comprehensive amplicon sequencing panel covering up to 276 targets, supports these applications but is tailored to research rather than routine programmatic use. We developed P. falciparum Public Health Amplicon Sequencing Tool (PfPHAST), a 56-target derivative of MAD 4 HatTeR spanning drug resistance loci, pfhrp2 / 3 deletion, PfCSP genotyping, non-falciparum species identification, and 20 high-heterozygosity microhaplotype loci for TES classification. We compared PfPHAST and MAD 4 HatTeR using laboratory strain controls, including two-strain dilution series and a five-strain mixture, across parasite densities of 100 to 10,000 parasites/µL. At matched per-target depth, PfPHAST achieved a higher quality-control pass rate than MAD4HatTeR (94.4% versus 90.0%) and distributed reads more evenly across targets. The panels showed comparable recall and precision for drug resistance codons and microhaplotypes, reaching near-complete recall above 40% within-sample allele frequency (WSAF) at all densities, with reduced sensitivity for minor alleles below 10% WSAF at low parasite density in both panels. Observed and expected WSAF correlated strongly for both panels, and both resolved a five-strain polyclonal mixture, including a 5% minor strain. By concentrating sequencing capacity on targets of greatest programmatic relevance, PfPHAST offers a scalable, lower-cost alternative to comprehensive research panels without sacrificing performance on shared targets, complementing MAD 4 HatTeR for routine molecular malaria surveillance.